Zoledronic acid given upfront maintains BMD in postmenopausal breast cancer patients

Study Type:Therapy

OE Level Evidence:2

Journal Level of Evidence:N/A

Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole

Cancer. 2012 Mar 1;118(5):1192-201. doi: 10.1002/cncr.26313. Epub 2011 Oct 10

Contributing Authors: AM Brufsky WG Harker JT Beck L Bosserman C Vogel C Seidler L Jin G Warsi E Argonza-Aviles J Hohneker SG Ericson EA Perez

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Dr. Adam M. Brufsky discusses the use of adjuvant zoledronic acid to maintain bone mass in postmenopausal breast cancer patients.

No credit card required

JOIN Forgot Password?

You could be earning 0.5 CME credits for each report you read.

LEARN MORE

Please Login or Join to leave comments.